NCT02487459View on ClinicalTrials.gov

Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Hematologic Malignancies
Interventions
BIOLOGICAL

BPX-501

T cells transduced with CaspaCIDe suicide gene

DRUG

AP1903

dimerizer drug administered to treat GVHD

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY